Experimental anti-GBM disease as a tool for studying spontaneous lupus nephritis

Clinical Immunology

Volumn 124, Issue 2, 2007, Pages 109-118

  Fu, Yuyang ^a   Du, Yong ^a   Mohan, Chandra ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Animal models; Genetics; Inflammation; Lupus; Nephritis

Indexed keywords

GLOMERULUS BASEMENT MEMBRANE ANTIBODY;

CELLULAR IMMUNITY; GENETIC SUSCEPTIBILITY; GLOMERULUS BASEMENT MEMBRANE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

ANIMALS; ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; DISEASE MODELS, ANIMAL; HUMANS; LUPUS NEPHRITIS; MICE; RATS; T-LYMPHOCYTES;

EID: 34447315527     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.05.007     Document Type: Short Survey

References (137)

1. Levy J.B., Lachman R.H., and Pusey C.D. Goodpasture's disease. Lancet 358 (2001) 917-920
2. Goodpasture E.W. The significance of certain pulmonary lesions in relation to the etiology of influenza. Am. J. Med. Sci. 158 (1919) 863-870
3. Stanton M.C., and Tange J.D. Goodpasture's syndrome (pulmonary haemorrhage associated with glomerulonephritis). Aust. Ann. Med. 7 (1958) 132-144
4. Lerner R.A., Glassock R.J., and Dixon F.J. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J. Exp. Med. 126 (1967) 989-1004
5. Wilson C.B., Holdsworth S.R., and Neale T.J. Anti-basementk membrane antibodies in immunologic renal disease. Aust. N.Z. J. Med. 11 (1981) 94-100
6. Fish A.J., Lockwood M.C., Wong M., and Price R.G. Detection of Goodpasture antigen in fractions prepared from collagenase digests of human glomerular basement membrane. Clin. Exp. Immunol. 55 (1984) 58-66
7. Wieslander J., Bygren P., and Heinegard D. Isolation of the specific glomerular basement membrane antigen involved in Goodpasture syndrome. Proc. Natl. Acad. Sci. U.S.A. 81 (1984) 1544-1548
8. Wieslander J., Barr J.F., Butkowski R.J., Edwards S.J., Bygren P., Heinegard D., and Hudson B.G. Goodpasture antigen of the glomerular basement membrane: localization to noncollagenous regions of type IV collagen. Proc. Natl. Acad. Sci. U.S.A. 81 (1984) 3838-3842
9. Butkowski R.J., Wieslander J., Wisdom B.J., Barr J.F., Noelken M.E., and Hudson B.G. Properties of the globular domain of type IV collagen and its relationship to the Goodpasture antigen. J. Biol. Chem. 260 (1985) 3739-3747
10. Butkowski R.J., Langeveld J.P., Wieslander J., Hamilton J., and Hudson B.G. Localization of the Goodpasture epitope to a novel chain of basement membrane collagen. J. Biol. Chem. 262 (1987) 7874-7877
11. Saus J., Wieslander J., Langeveld J.P., Quinones S., and Hudson B.G. Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV. J. Biol. Chem. 263 (1988) 13374-13380
12. Neilson E.G., Kalluri R., Sun M.J., Gunwar S., Danoff T., Mariyama M., Myers J.C., Reeders S.T., and Hudson B.G. Specificity of Goodpasture autoantibodies for the recombinant noncollagenous domains of human type IV collagen. J. Biol. Chem. 268 (1993) 8402-8405
13. Turner N., Forstova J., Rees A., Pusey C.D., and Mason P.J. Production and characterization of recombinant Goodpasture antigen in insect cells. J. Biol. Chem. 269 (1994) 17141-17145
14. Netzer K.O., Leinonen A., Boutaud A., Borza D.B., Todd P., Gunwar S., Langeveld J.P., and Hudson B.G.A. The Goodpasture autoantigen. Mapping the major conformational epitope (s) of alpha3(IV) collagen to residues 17-31 and 127-141 of the NC1 domain. J. Biol. Chem. 274 (1999) 11267-11274
15. Dehan P., Weber M., Zhang X., Reeders S.T., Foidart J.M., and Tryggvason K. Sera from patients with anti-GBM nephritis including Goodpasture syndrome show heterogenous reactivity to recombinant NC1 domain of type IV collagen alpha chains. Nephrol. Dial. Transplant. 11 (1996) 2215-2222
16. Pusey C.D. Anti-glomerular basement membrane disease. Kidney Int. 4 (2003) 1535-1550
17. Borza D.B., Neilson E.G., and Hudson BG. Pathogenesis of Goodpasture syndrome: a molecular perspective. Semin. Nephrol. 23 (2003) 522-531
18. Sado Y., Naito I., Akita M., and Okigaki T. Strain specific responses of inbred rats on the severity of experimental autoimmune glomerulonephritis. J. Clin. Lab. Immunol. 19 (1986) 193-199
19. Sado Y., and Naito I. Experimental autoimmune glomerulonephritis in rats by soluble isologous or homologous antigens from glomerular and tubular basement membranes. Br. J. Exp. Pathol. 68 (1987) 695-704
20. Bolton W.K., May W.J., and Sturgill B.C. Proliferative autoimmune-glomerulonephritis in rats: a model for autoimmune glomerulonephritis in humans. Kidney Int. 44 (1993) 294-306
21. Fukuda Y., Yamanaka N., Ishizaki M., Suzuki T., Masugi Y., Yajima G., and Nagata T. Immune complex-mediated glomerulonephritis and interstitial pneumonia simulating Goodpasture's syndrome. Acta Pathol. Jpn. 32 (1982) 361-370
22. Xie C., Sharma R., Wang H., Zhou X.J., and Mohan C. Strain distribution pattern of susceptibility to immune-mediated nephritis. J. Immunol. 172 (2004) 5047-5055
23. Xie C., Zhou X.J., Liu X., and Mohan C. Enhanced susceptibility to end-organ disease in the lupus-facilitating NZW mouse strain. Arthritis Rheum. 48 (2003) 1080-1092
24. Swaak A.J., Huysen V., Nossent J.C., and Smeenk R.J. Antinuclear antibody profiles in relation to specific disease manifestations of systemic lupus erythematosus. Clin. Rheumatol. 9 (1990) 82-94
25. Vlahakos D.V., Foster M.H., Adams S., Katz M., Ucci A.A., Barrett K.J., Datta S.K., and Madaio M.P. Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int. 41 (1992) 1690-1700
26. Raz E., Brezis M., Rosenmann E., and Eilat D. Anti-DNA antibodies bind directly to renal antigens and induce kidney dysfunction in the isolated perfused rat kidney. J. Immunol. 142 (1989) 3076-3082
27. Limaye N., and Mohan C. Pathogenicity of anti-DNA and anti-glomerular antibodies: weighing the evidence. Drug Discov. Today: Dis. Models 1 (2004) 395-403
28. Lefkowith J.B., and Gilkeson G.S. Nephritogenic autoantibodies in lupus. Current concepts and continuing controversies. Arthritis Rheum. 39 (1996) 894-903
29. Nolasco F.E., Cameron J.S., Hartley B., Coelho A., Hildreth G., and Reuben R. Intraglomerular T cells and monocytes in nephritis: study with monoclonal antibodies. Kidney Int. 31 (1987) 1160-1166
30. Li H.L., Hancock W.W., Dowling J.P., and Atkins R.C. Activated (IL-2R+) intraglomerular mononuclear cells in crescentic glomerulonephritis. Kidney Int. 39 (1991) 793-798
31. Merkel F., Kalluri R., Marx M., Enders U., Stevanovic S., Giegerich G., Neilson E.G., Rammensee H.G., Hudson B.G., and Weber M. Autoreactive T-cells in Goodpasture's syndrome recognize the N-terminal NC1 domain on alpha 3 type IV collagen. Kidney Int. 49 (1996) 1127-1133
32. Derry C.J., Ross C.N., Lombardi G., Mason P.D., Rees A.J., Lechler R.I., and Pusey C.D. Analysis of T cell responses to the autoantigen in Goodpasture's disease. Clin. Exp. Immunol. 100 (1995) 262-268
33. Tipping P.G., Huang X.R., Qi M., Van G.Y., and Tang W.W. Crescentic glomerulonephritis in CD4- and CD8-deficient mice. Requirement for CD4 but Not CD8 Cells. Am. J. Pathol. 152 (1998) 1541-1548
34. Reynolds J., and Pusey C.D. In vivo treatment with a monoclonal antibody to T helper cells in experimental autoimmune glomerulonephritis in the BN rat. Clin. Exp. Immunol. 95 (1994) 122-127
35. Nishikawa K., Linsley P.S., Collins A.B., Stamenkovic I., McCluskey R.T., and Andres G. Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis. Eur. J. Immunol. 24 (1994) 1249-1254
36. Reynolds J., Tam F.W., Chandraker A., Smith J., Karkar A.M., Cross J., Peach R., Sayegh M.H., and Pusey C.D. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J. Clin. Invest. 105 (2000) 643-651
37. Reynolds J., Khan S.B., Allen A.R., Benjamin C.D., and Pusey C.D. Blockade of the CD154-CD40 costimulatory pathway prevents the development of experimental autoimmune glomerulonephritis. Kidney Int. 66 (2004) 1444-1452
38. Nishikawa K., Guo Y.J., Miyasaka M., Tamatani T., Collins A.B., Sy M.S., and McCluskey R.T. Antibodies to intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 prevent crescent formation in rat autoimmune glomerulonephritis. J. Exp. Med. 177 (1993) 667-677
39. Kalluri R., Danoff T.M., Okada H., and Neilson E.G. Susceptibility to anti-glomerular basement membrane disease and Goodpasture syndrome is linked to MHC class II genes and the emergence of T cell-mediated immunity in mice. J. Clin. Invest. 100 (1997) 2263-2275
40. Nitta K., Horita S., Ogawa S., Matsumoto M., Hara Y., Okano K., Hayashi T., Abe R., and Nihei H. Resistance of CD28-deficient mice to autologous phase of anti-glomerular basement membrane glomerulonephritis. Clin. Exp. Nephrol. 7 (2003) 104-112
41. Janssen U., Ostendorf T., Gaertner S., Eitner F., Hedrich H.J., Assmann K.J., and Floege J. Improved survival and amelioration of nephrotoxic nephritis in intercellular adhesion molecule-1 knockout mice. J. Am. Soc. Nephrol. 9 (1998) 1805-1814
42. Li S., Kurts C., Kontgen F., Holdsworth S.R., and Tipping P.G. Major histocompatibility complex class II expression by intrinsic renal cells is required for crescentic glomerulonephritis. J. Exp. Med. 188 (1998) 597-602
43. Reynolds J., Norgan V.A., Bhambra U., Smith J., Cook H.T., and Pusey C.D. Anti-CD8 monoclonal antibody therapy is effective in the prevention and treatment of experimental autoimmune glomerulonephritis. J. Am. Soc. Nephrol. 13 (2002) 359-369
44. Kawasaki K., Yaoita E., Yamamoto T., and Kihara I. Depletion of CD8 positive cells in nephrotoxic serum nephritis of WKY rats. Kidney Int. 41 (1992) 1517-1526
45. Wu J., Borillo J., Glass II W.F., Hicks J., Ou C.N., and Lou Y.J. T cell epitope of glomerular basement membrane antigen induces severe glomerulonephritis. Kidney Int. 64 (2003) 1292-1301
46. + T cells specific to glomerular basement membrane antigen induce glomerulonephritis. J. Clin. Invest. 109 (2002) 517-524
47. Wu J., Hicks J., Ou C.N., Singleton D., Borillo J., and Lou Y.H. Glomerulonephritis induced by recombinant Col4α3NC1 is not associated with antibody to GBM: a potential T cell mediated mechanism. J. Immunol. 167 (2001) 2388-2395
48. Wu J., Arends J., Borillo J., Zhou C., Merszei J., McMahon J., and Lou Y.H. A self T cell epitope induces autoantibody response: mechanism for production of antibodies to diverse glomerular basement membrane antigens. J. Immunol. 172 (2004) 4567-4574
49. Lou Y.H. Anti-GBM glomerulonephritis: a T cell-mediated autoimmune disease?. Arch. Immunol. Ther. Exp. 52 (2004) 96-103
50. Takeuchi T., Tsuzaka K., Abe T., Yoshimoto K., Shiraishi K., Kameda H., and Amano K. T cell abnormalities in systemic lupus erythematosus. Autoimmunity 38 (2005) 339-346
51. Diaz Gallo C., Jevnikar A.M., Brennan D.C., Florquin S., Pacheco-Silva A., and Kelley V.R. Autoreactive kidney-infiltrating T-cell clones in murine lupus nephritis. Kidney Int. 42 (1992) 851-859
52. Giese T., and Davidson W.F. Evidence for early onset, polyclonal activation of T cell subsets in mice homozygous for lpr. J. Immunol. 149 (1992) 3097-3106
53. Chen F.Q., Maldonado M.A., Madaio M., and Eisenberg R.A. The role of host (endogenous) T cells in chronic graft-versus-host autoimmune disease. J. Immunol. 161 (1998) 5880-5885
54. Adachi Y., Inaba M., Sugihara A., Koshiji M., Sugiura K., Amoh Y., Mori S., Kamiya T., Genba H., and Ikehara S. Effects of administration of monoclonal antibodies (anti-CD4 or anti-CD8) on the development of autoimmune diseases in (NZW × BXSB) F1 mice. Immunobiology 98 (1998) 451-464
55. Maeda T., and Nomoto K. Anti-T cell receptor antibody treatment of mice with lupus-like graft versus host disease: suppression of glomerulonephritis without reduction in anti-DNA antibody levels. J. Rheumatol. 22 (1995) 2259-2265
56. Kootstra C.J., Van Der Giezen D.M., Van Krieken J.H., De Heer E., and Bruijn J.A. Effective treatment of experimental lupus nephritis by combined administration of anti-CD11a and anti-CD54 antibodies. Clin. Exp. Immunol. 108 (1997) 324-332
57. Finck B.K., Linsley P.S., and Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 265 (1994) 1225-1227
58. Nakajima A., Azuma M., Kodera S., Nuriya S., Terashi A., Abe M., Hirose S., Shirai T., Yagita H., and Okumura K. Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule. Eur. J. Immunol. 25 (1995) 3060-3069
59. Daikh D.I., Finck B.K., Linsley P.S., Hollenbaugh D., and Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J. Immunol. 159 (1997) 3104-3108
60. Mohan C., Shi Y., Laman J.D., and Datta S.K. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. Immunology 154 (1995) 1470-1480
61. Pollard K.M., Arnush M., Hultman P., and Kono D.H. Costimulation requirements of induced murine systemic autoimmune disease. J. Immunol. 173 (2004) 5880-5887
62. Foell J., Strahotin S., O'Neil S.P., McCausland M.M., Suwyn C., Haber M., Chander P.N., Bapat A.S., Yan X.J., Chiorazzi N., Hoffmann M.K., and Mittler R.S. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB × ZW F1 mice. J. Clin. Invest. 111 (2003) 1505-1518
63. Tada Y., Nagasawa K., Ho A., Morito F., Koarada S., Ushiyama O., Suzuki N., Ohta A., and Mak T.W. Role of the costimulatory molecule CD28 in the development of lupus in MRL/lpr mice. J. Immunol. 163 (1999) 3153-3159
64. Ogawa S., Nitta K., Hara Y., Horita S., Nihei H., and Abe R. CD28 knockout mice as a useful clue to examine the pathogenesis of chronic graft-versus-host reaction. Kidney Int. 58 (2000) 2215-2220
65. Bullard D.C., King P.D., Hicks M.J., Dupont B., Beaudet A.L., and Elkon KB. Intercellular adhesion molecule-1 deficiency protects MRL/MpJ-Fas(lpr) mice from early lethality. J. Immunol. 159 (1997) 2058-2067
66. Kevil C.G., Hicks M.J., He X., Zhang J., Ballantyne C.M., Raman C., Schoeb T.R., and Bullard D.C. Loss of LFA-1, but not Mac-1, protects MRL/MpJ-Fas(lpr) mice from autoimmune disease. Am. J. Pathol. 165 (2004) 609-616
67. Mozes E., Kohn L.D., Hakim F., and Singer D.S. Resistance of MHC class I-deficient mice to experimental systemic lupus erythematosus. Science 261 (1993) 91-93
68. Jevnikar A.M., Grusby M.J., and Glimcher L.H. Prevention of nephritis in major histocompatibility complex class II-deficient MRL-lpr mice. J. Exp. Med. 179 (1994) 1137-1143
69. Kinoshita K., Tesch G., Schwarting A., Maron R., Sharpe A.H., and Kelley V.R. Costimulation by B7-1 and B7-2 is required for autoimmune disease in MRL-Faslpr mice. J. Immunol. 164 (2000) 6046-6056
70. Waters S.T., McDuffie M., Bagavant H., Deshmukh U.S., Gaskin F., Jiang C., Tung K.S., and Fu S.M. Breaking tolerance to double D.N.A. stranded, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis. J. Exp. Med. 199 (2004) 255-264
71. Rother R.P., Mojcik C.F., and McCroskery E.W. Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus. Lupus 13 (2004) 328-334
72. Feith G.W., Assmann K.J., Bogman M.J., van Gompel A.P., Schalkwijk J., and Koene R.A. Different mediator systems in biphasic heterologous phase of anti-GBM nephritis in mice. Nephrol. Dial. Transplant. 11 (1996) 599-607
73. Hebert M.J., Takano T., Papayianni A., Rennke H.G., Minto A., Salant D.J., Carroll M.C., and Brady H.R. Acute nephrotoxic serum nephritis in complement knockout mice: relative roles of the classical and alternate pathways in neutrophil recruitment and proteinuria. Nephrol. Dial. Transplant. 13 (1998) 2799-2803
74. Sheerin N.S., Springall T., Abe K., and Sacks S.H. Protection and injury: the differing roles of complement in the development of glomerular injury. Eur. J. Immunol. 31 (2001) 1255-1260
75. Quigg R.J., Kozono Y., Berthiaume D., Lim A., Salant D.J., Weinfeld A., Griffin P., Kremmer E., and Holers V.M. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J. Immunol. 160 (1998) 4553-4560
76. Bao L., Zhou J., Holers V.M., and Quigg R.J. Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependent on complement activation. J. Am. Soc. Nephrol. 14 (2003) 2516-2525
77. Takai T., Li M., Sylvestre D., Clynes R., and Ravetch J.V. FcR gamma chain deletion results in pleiotropic effector cell defects. Cell 76 (1994) 519-529
78. Clynes R., and Ravetch J.V. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity 3 (1995) 21-26
79. Park S.Y., Ueda S., Ohno H., Hamano Y., Tanaka M., Shiratori T., Yamazaki T., Arase H., Arase N., Karasawa A., Sato S., Ledermann B., Kondo Y., Okumura K., Ra C., and Saito T. Resistance of Fc receptor-deficient mice to fatal glomerulonephritis. J. Clin. Invest. 102 (1998) 1229-1238
80. Sylvestre D.L., and Ravetch J.V. Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science 265 (1994) 1095-1098
81. Hazenbos W.L., Gessner J.E., Hofhuis F.M., Kuipers H., Meyer D., Heijnen I.A., Schmidt R.E., Sandor M., Capel P.J., Daeron M., van de Winkel J.G., and Verbeek J.S. Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity 5 (1996) 181-188
82. Sylvestre D.L., and Ravetch J.V. A dominant role for mast cell Fc receptors in the Arthus reaction. Immunity 5 (1996) 387-390
83. Sylvestre D., Clynes R., Ma M., Warren H., Carroll M.C., and Ravetch J.V. Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. J. Exp. Med. 184 (1996) 2385-2392
84. Suzuki Y., Shirato I., Okumura K., Ravetch J.V., Takai T., Tomino Y., and Ra C. Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis. Kidney Int. 54 (1998) 1166-1174
85. Park S.Y., Ueda S., Ohno H., Hamano Y., Tanaka M., Shiratori T., Yamazaki T., Arase H., Arase N., Karasawa A., Sato S., Ledermann B., Kondo Y., Okumura K., Ra C., and Saito T. Resistance of Fc receptor-deficient mice to fatal glomerulonephritis. J. Clin. Invest. 102 (1998) 1229-1238
86. Clynes R., Dumitru C., and Ravetch J.V. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 279 (1998) 1052-1054
87. Le Hir M., Haas C., Marino M., and Ryffel B. Prevention of crescentic glomerulonephritis induced by anti-glomerular membrane antibody in tumor necrosis factor-deficient mice. Lab. Invest. 78 (1998) 1625-1631
88. Karkar A.M., Smith J., and Pusey C.D. Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor-alpha. Nephrol. Dial. Transplant. 16 (2001) 518-524
89. Brennan D.C., Yui M.A., Wuthrich R.P., and Kelley V.E. Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J. Immunol. 143 (1989) 3470-3475
90. McHale J.F., Harari O.A., Marshall D., and Haskard D.O. TNF-alpha and IL-1 sequentially induce endothelial ICAM-1 and VCAM-1 expression in MRL/lpr lupus-prone mice. J. Immunol. 163 (1999) 3993-4000
91. Sun H., Liu W., and Shao J. Study of immunoregulation by interleukin-1 receptor antagonist in NZB/W F1 mice. Zhonghua Yi Xue ZaZhi 76 (1996) 600-602
92. Tang W.W., Feng L., Vannice J.L., and Wilson C.B. Interleukin-1 receptor antagonist ameliorates experimental anti-glomerular basement membrane antibody-associated glomerulonephritis. J. Clin. Invest. 93 (1994) 273-279
93. Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu. Rev. Immunol. 23 (2005) 1-21
94. Hattori T., Fujitsuka N., Kurogi A., and Shindo S. Effects of neutralizing antibodies on cytokine treatment for anti-GBM nephritis in mouse. Nippon Jinzo Gakkaishi 38 (1996) 563-570
95. Liang B., Gardner D.B., Griswold D.E., Bugelski P.J., and Song X.Y. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 119 (2006) 296-305
96. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev., Immunol. 3 (2003) 133-146
97. Timoshanko J.R., Kitching A.R., Holdsworth S.R., and Tipping P.G. Interleukin-12 from intrinsic cells is an effector of renal injury in crescentic glomerulonephritis. J. Am. Soc. Nephrol. 12 (2001) 464-471
98. Schwarting A., Tesch G., Kinoshita K., Maron R., Weiner H.L., and Kelley V.R. IL-12 drives IFN-gamma-dependent autoimmune kidney disease in MRL-Fas(lpr) mice. J. Immunol. 163 (1999) 6884-6891
99. Balabanov R., Strand K., Goswami R., McMahon E., Begolka W., Miller S.D., and Popko B. Interferon-gamma-oligodendrocyte interactions in the regulation of experimental autoimmune encephalomyelitis. J. Neurosci. 27 (2007) 2013-2024
100. Kitching A.R., Holdsworth S.R., and Tipping P.G. IFN-gamma mediates crescent formation and cell-mediated immune injury in murine glomerulonephritis. J. Am. Soc. Nephrol. 10 (1999) 752-759
101. Schwarting A., Wada T., Kinoshita K., Tesch G., and Kelley V.R. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J. Immunol. 161 (1998) 494-503
102. Kitching A.R., Turner A.L., Semple T., Li M., Edgtton K.L., Wilson G.R., Timoshanko J.R., Hudson B.G., and Holdsworth S.R. Experimental autoimmune anti-glomerular basement membrane glomerulonephritis: a protective role for IFN-gamma. J. Am. Soc. Nephrol. 15 (2004) 1764-1774
103. Gasson J.C. Molecular physiology of granulocyte-macrophage stimulating factor. Blood 77 (1991) 1131-1145
104. Kitching A.R., Ru Huang X., Turner A.L., Tipping P.G., Dunn A.R., and Holdsworth S.R. The requirement for granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in leukocyte-mediated immune glomerular injury. J. Am. Soc. Nephrol. 13 (2002) 350-358
105. Bloom R.D., Florquin S., Singer G.G., Brennan D.C., and Kelley V.R. Colony stimulating factor-1 in the induction of lupus nephritis. Kidney Int. 43 (1993) 1000-1009
106. Lenda D.M., Stanley E.R., and Kelley V.R. Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Fas(lpr) mice. J. Immunol. 173 (2004) 4744-4754
107. Gesualdo L., Di Paolo S., Milani S., Pinzani M., Grappone C., Ranieri E., Pannarale G., and Schena F.P. Expression of platelet-derived growth factor receptors in normal and diseased human kidney. An immunohistochemistry and in situ hybridization study. J. Clin. Invest. 94 (1994) 50-58
108. Ostendorf T., Rong S., Boor P., Wiedemann S., Kunter U., Haubold U., van Roeyen C.R., Eitner F., Kawachi H., Starling G., Alvarez E., Smithson G., and Floege J. Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. J. Am. Soc. Nephrol. 17 (2006) 1054-1062
109. Sadanaga A., Nakashima H., Masutani K., Miyake K., Shimizu S., Igawa T., Sugiyama N., Niiro H., Hirakata H., and Harada M. Amelioration of autoimmune nephritis by Imatinib in MRL/lpr mice. Arthritis Rheum. 52 (2005) 3987-3996
110. Vielhauer V., Anders H.J., and Schlondorff D. Chemokines and chemokine receptors as therapeutic targets in lupus nephritis. Semin. Nephrol. 27 (2007) 81-97
111. Shimizu S., Nakashima H., Masutani K., Inoue Y., Miyake K., Akahoshi M., Tanaka Y., Egashira K., Hirakata H., Otsuka T., and Harada M. Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Rheumatology (Oxford) 43 (2004) 1121-1128
112. Tesch G.H., Schwarting A., Kinoshita K., Lan H.Y., Rollins B.J., and Kelley V.R. Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis. J. Clin. Invest. 103 (1999) 73-80
113. Bao L., Haas M., Boackle S.A., Kraus D.M., Cunningham P.N., Park P., Alexander J.J., Anderson R.K., Culhane K., Holers V.M., and Quigg R.J. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J. Immunol. 168 (2004) 3601-3607
114. Bao L., Osawe I., Puri T., Lambris J.D., Haas M., and Quigg R.J. C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur. J. Immunol. 35 (2005) 2496-2506
115. Huugen D., van Esch A., Xiao H., Peutz-Kootstra C.J., Buurman W.A., Tervaert J.W., Jennette J.C., and Heeringa P. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int. 71 (2007) 646-654
116. Brown H.J., Sacks S.H., and Robson M.G. Toll-like receptor 2 agonists exacerbate accelerated nephrotoxic nephritis. J. Am. Soc. Nephrol. 17 (2006) 1931-1939
117. Fu Y., Xie C., Chen J., Zhu J., Zhou H., Thomas J., Zhou X.J., and Mohan C. Innate stimuli accentuate end-organ damage by nephrotoxic antibodies via Fc receptor and TLR stimulation and IL-1/TNF-alpha production. J. Immunol. 176 (2006) 632-639
118. Patole P.S., Grone H.J., Segerer S., Ciubar R., Belemezova E., Henger A., Kretzler M., Schlondorff D., and Anders H.J. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J. Am. Soc. Nephrol. 16 (2005) 1326-1338
119. Anders H.J., Vielhauer V., Eis V., Linde Y., Kretzler M., Perez de Lema G., Strutz F., Bauer S., Rutz M., Wagner H., Grone H.J., and Schlondorff D. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J. 18 (2004) 534-536
120. Pawar R.D., Patole P.S., Ellwart A., Lech M., Segerer S., Schlondorff D., and Anders H.J. Ligands to nucleic acid-specific toll-like receptors and the onset of lupus nephritis. J. Am. Soc. Nephrol. 17 (2006) 3365-3373
121. Anders H.J., Banas B., Linde Y., Weller L., Cohen C.D., Kretzler M., Martin S., Vielhauer V., Schlondorff D., and Grone H.J. Bacterial CpG-DNA aggravates immune complex glomerulonephritis: role of TLR9-mediated expression of chemokines and chemokine receptors. J. Am. Soc. Nephrol. 14 (2003) 317-326
122. Iwai H., Abe M., Hirose S., Tsushima F., Tezuka K., Akiba H., Yagita H., Okumura K., Kohsaka H., Miyasaka N., and Azuma M. Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis. J. Immunol. 15 171 (2003) 2848-2854
123. Daikh D.I., and Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol. 166 (2001) 2913-2916
124. Schiffer L., Sinha J., Wang X., Huang W., von Gersdorff G., Schiffer M., Madaio M.P., and Davidson A. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J. Immunol. 171 (2003) 489-497
125. Kalled S.L., Cutler A.H., and Ferrant J.L. Long-term anti-CD154 dosing in nephritic mice is required to maintain survival and inhibit mediators of renal fibrosis. Lupus 10 (2001) 9-22
126. Mayadas T.N., Mendrick D.L., Brady H.R., Tang T., Papayianni A., Assmann K.J., Wagner D.D., Hynes R.O., and Cotran R.S. Acute passive anti-glomerular basement membrane nephritis in P-selectin-deficient mice. Kidney Int. 49 (1996) 1342-1349
127. Ogawa D., Shikata K., Matsuda M., Okada S., Wada J., Yamaguchi S., Suzuki Y., Miyasaka M., Tojo S., and Makino H. Preventive effect of sulphated colominic acid on P-selectin-dependent infiltration of macrophages in experimentally induced crescentic glomerulonephritis. Clin. Exp. Immunol. 129 (2002) 1-3
128. He X., Schoeb T.R., Panoskaltsis-Mortari A., Zinn K.R., Kesterson R.A., Zhang J., Samuel S., Hicks M.J., Hickey M.J., and Bullard D.C. Deficiency of P-selectin or P-selectin glycoprotein ligand-1 leads to accelerated development of glomerulonephritis and increased expression of CC chemokine ligand 2 in lupus-prone mice. J. Immunol. 177 (2006) 8748-8756
129. De Vriese A.S., Endlich K., Elger M., Lameire N.H., Atkins R.C., Lan H.Y., Rupin A., Kriz W., and Steinhausen M.W. The role of selectins in glomerular leukocyte recruitment in rat anti-glomerular basement membrane glomerulonephritis. J. Am. Soc. Nephrol. 10 (1999) 2510-2517
130. Kitching A.R., Tipping P.G., Kurimoto M., and Holdsworth S.R. L-18 has IL-12-independent effects in delayed-type hypersensitivity: studies in cell-mediated crescentic glomerulonephritis. J. Immunol. 165 (2000) 4649-4657
131. Kitching A.R., Turner A.L., Wilson G.R., Semple T., Odobasic D., Timoshanko J.R., O'Sullivan K.M., Tipping P.G., Takeda K., Akira S., and Holdsworth S.R. IL-12p40 and IL-18 in crescentic glomerulonephritis: IL-12p40 is the key Th1-defining cytokine chain, whereas IL-18 promotes local inflammation and leukocyte recruitment. J. Am. Soc. Nephrol. 16 (2005) 2023-2033
132. Kinoshita K., Yamagata T., Nozaki Y., Sugiyama M., Ikoma S., Funauchi M., and Kanamaru A. Blockade of IL-18 receptor signaling delays the onset of autoimmune disease in MRL-Faslpr mice. J. Immunol. 173 (2004) 5312-5318
133. Utsunomiya Y., Omura K., Yokoo T., Imasawa T., Kawamura T., Abe A., Hirano K., Mitarai T., Maruyama N., and Sakai O. Macrophage-colony stimulating factor (M-CSF) enhances proteinuria and recruitment of macrophages into the glomerulus in experimental murine nephritis. Clin. Exp. Immunol. 106 (1996) 286-296
134. Haas C., Ryffel B., and Le Hir M. Crescentic glomerulonephritis in interferon-gamma receptor deficient mice. J. Inflamm. 47 (1995-1996) 206-213
135. Narita I., Border W.A., Ketteler M., and Noble N.A. Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis. Lab. Invest. 72 (1995) 1-3
136. Bremer V., Tojo A., Kimura K., Hirata Y., Goto A., Nagamatsu T., Suzuki Y., and Omata M. Role of nitric oxide in rat nephrotoxic nephritis: comparison between inducible and constitutive nitric oxide synthase. J. Am. Soc. Nephrol. 8 (1997) 1712-1721
137. Reilly C.M., Farrelly L.W., Viti D., Redmond S.T., Hutchison F., Ruiz P., Manning P., Connor J., and Gilkeson G.S. Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase. Kidney Int. 61 (2002) 839-846